Abstract
Objective To identify potential serum biomarkers in women with peritoneal endometriosis (PE) by first looking at its source in the peritoneal fluid (PF).
Design Case-control pilot studies, comprising independent discovery and validation sets.
Setting KK Women’s and Children’s Hospital, Singapore.
Patient(s) Women with laparoscopically confirmed PE and absence of endometriosis (control).
Intervention(s) None.
Main Outcome Measure(s) In the discovery set, we used untargeted liquid chromatography-mass spectrometry (LC-MS/MS) metabolomics, multivariable and univariable analyses to generate global metabolomic profiles of PF for endometriosis and to identify potential metabolites that could distinguish PE (n=10) from controls (n=31). Using targeted metabolomics, we validated the identified metabolites in PF and sera of cases (n=16 PE) and controls (n=19). We performed the area under the receiver-operating characteristics curve (AUC) analysis to evaluate the diagnostic performance of PE metabolites.
Result(s) In the discovery set, PF phosphatidylcholine (34:3) and phenylalanyl-isoleucine were significantly increased in PE than controls groups, with AUC 0.77 (95% confidence interval 0.61-0.92; p=0.018) and AUC 0.98 (0.95-1.02; p<0.001), respectively. In the validation set, phenylalanyl-isoleucine retained discriminatory performance to distinguish PE from controls in both PF (AUC 0.77; 0.61-0.92; p=0.006) and serum samples (AUC 0.81; 0.64-0.99; p=0.004).
Conclusion(s) Our preliminary results propose phenylalanyl-isoleucine as a potential biomarker of PE, which may be used as a minimally-invasive diagnostic biomarker of PE.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
This is an observational study, not a clinical trial.
Funding Statement
This work was supported by the National Research Foundation Singapore under its National Medical Research Council Centre Grant Program (NMRC/CG/M003/2017) and administered by the Singapore Ministry of Health’s National Medical Research Council, and Duke-NUS Office of Academic Medicine (Clinical and Translational Research in Endometriosis). JCKY received salary support from Singapore’s Ministry of Health’s National Medical Research Council (CSA-SI-008-2016).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Singhealth Centralized Institutional Review Board (reference 2010-167-D)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Raw data are available from the corresponding author.
